Everest Medicines to Announce First Half 2023 Financial Results on August 24, 2023
Shanghai, China – August 9, 2023 – Everest Medicines (HKEX 1952.HK, “Everest”, or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the first half of 2023 ended June 30, 2023 and provide a business update on August 24, 2023. The Company will hold a live conference call in English and Mandarin on August 24, 2023 Beijing Time.
The English session of the conference call will be held at 9:00 AM on August 24, 2023 Beijing Time (9:00 PM U.S. Eastern Time on August 23, 2023) and the Mandarin session of the conference call will be held at 3:30 PM Beijing Time on the same day (3:30 AM U.S. Eastern Time on August 24, 2023).
The conference calls can be accessed by the following links:
For English Session:
Time: 9:00 AM Beijing Time, Thursday, August 24, 2023
Pre-Registration Link: https://www.acecamptech.com/eventDetail/60504030
Webcast Link: https://www.acecamptech.com/meeting_live/70505775/4998?event_id=60504030
Alternatively, participants may dial in to the conference call using below dial-in information:
United States: +1-646-2543594 (EN)
Chinese Mainland: +86-10-58084166 (EN)
Hong Kong, China: +852-30051313 (EN)
United Kingdom: +44-20-76600166 (EN)
International: +1-866-6363243 (EN)
For Mandarin Session:
Time: 3:30 PM Beijing Time, Thursday, August 24, 2023
Webcast Link: https://s.comein.cn/A12FL
Alternatively, participants may dial into the conference call using below dial-in information:
United States: +1-202-5524791
Chinese Mainland: +86-400-188-8938
Hong Kong, China:
Taiwan, China: +852-57006920
United Kingdom: +44-2034816288
The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include renal diseases, infectious diseases, mRNA platform and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.
For further information, please contact:
Leah Liu, VP Corporate Affairs
Media in Asia:
Jing Yang, Everest Medicines
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.